Hartmut Rehwinkel

Summary

Affiliation: Schering AG
Country: Germany

Publications

  1. ncbi request reprint GR ligands: can we improve the established drugs?
    Hartmut Rehwinkel
    Schering AG, Corporate Research, Medicinal Chemistry, 13342 Berlin, Germany
    ChemMedChem 1:803-5. 2006
  2. ncbi request reprint Insight into the molecular mechanisms of glucocorticoid receptor action promotes identification of novel ligands with an improved therapeutic index
    Heike Schäcke
    CRBA Inflammation, Corporate Research, Schering AG, Berlin, Germany
    Exp Dermatol 15:565-73. 2006
  3. ncbi request reprint Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index
    Heike Schäcke
    Bayer Schering Pharma AG, Global Drug Discovery, TRG Inflammation Immunology, Müllerstr 178, 13342 Berlin, Germany
    Mol Cell Endocrinol 275:109-17. 2007
  4. ncbi request reprint Dissociated glucocorticoid receptor ligands
    Heike Schäcke
    Schering AG, Corporate Research, Mullerstrasse 178, 13342 Berlin, Germany
    Curr Opin Investig Drugs 5:524-8. 2004
  5. ncbi request reprint Dissociated glucocorticoid receptor ligands: compounds with an improved therapeutic index
    Heike Schäcke
    Schering AG, RBA Dermatology Europe, 13342 Berlin, Germany
    Curr Opin Investig Drugs 6:503-7. 2005
  6. pmc Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects
    Heike Schäcke
    Corporate Research Business Area Dermatology, Corporate Project Management Strategic Business Unit Specialized Therapeutics, and Medicinal Chemistry, Schering AG, Berlin, D 13342 Berlin, Germany
    Proc Natl Acad Sci U S A 101:227-32. 2004
  7. ncbi request reprint Fluorinated dihydroquinolines as potent n-NOS inhibitors
    Stefan Jaroch
    Medicinal Chemistry, Corporate Research, Research Center Europe, Schering AG, D 13342 Berlin, Germany
    Bioorg Med Chem Lett 14:743-6. 2004
  8. ncbi request reprint Dihydroquinolines as novel n-NOS inhibitors
    Stefan Jaroch
    Department of Medicinal Chemistry, Corporate Research, Schering AG, D 13342 Berlin, Germany
    Bioorg Med Chem Lett 12:2561-4. 2002
  9. ncbi request reprint Dihydroquinolines with amine-containing side chains as potent n-NOS inhibitors
    Stefan Jaroch
    Department of Medicinal Chemistry, Research Center Europe, Corporate Research, Schering AG, D 13342, Berlin, Germany
    Bioorg Med Chem Lett 13:1981-4. 2003

Detail Information

Publications9

  1. ncbi request reprint GR ligands: can we improve the established drugs?
    Hartmut Rehwinkel
    Schering AG, Corporate Research, Medicinal Chemistry, 13342 Berlin, Germany
    ChemMedChem 1:803-5. 2006
  2. ncbi request reprint Insight into the molecular mechanisms of glucocorticoid receptor action promotes identification of novel ligands with an improved therapeutic index
    Heike Schäcke
    CRBA Inflammation, Corporate Research, Schering AG, Berlin, Germany
    Exp Dermatol 15:565-73. 2006
    ..Nevertheless, considerable improvement in the therapeutic action of glucocorticoid receptor ligands is being achieved through the use of key molecular targets for screening novel glucocorticoid receptor ligands...
  3. ncbi request reprint Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index
    Heike Schäcke
    Bayer Schering Pharma AG, Global Drug Discovery, TRG Inflammation Immunology, Müllerstr 178, 13342 Berlin, Germany
    Mol Cell Endocrinol 275:109-17. 2007
    ..Such selective GR agonists (SEGRAs) are likely to enter clinical testing soon...
  4. ncbi request reprint Dissociated glucocorticoid receptor ligands
    Heike Schäcke
    Schering AG, Corporate Research, Mullerstrasse 178, 13342 Berlin, Germany
    Curr Opin Investig Drugs 5:524-8. 2004
    ..Several pharmaceutical companies are currently pursuing this goal...
  5. ncbi request reprint Dissociated glucocorticoid receptor ligands: compounds with an improved therapeutic index
    Heike Schäcke
    Schering AG, RBA Dermatology Europe, 13342 Berlin, Germany
    Curr Opin Investig Drugs 6:503-7. 2005
    ..Compounds that preferentially induce transrepression rather than transactivation should be superior to classical glucocorticoids. Indeed, proof of concept has been recently achieved with such selective glucocorticoid receptor agonists...
  6. pmc Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects
    Heike Schäcke
    Corporate Research Business Area Dermatology, Corporate Project Management Strategic Business Unit Specialized Therapeutics, and Medicinal Chemistry, Schering AG, Berlin, D 13342 Berlin, Germany
    Proc Natl Acad Sci U S A 101:227-32. 2004
    ..Moreover, they are useful tool compounds for further investigating the mechanisms of GR-mediated effects...
  7. ncbi request reprint Fluorinated dihydroquinolines as potent n-NOS inhibitors
    Stefan Jaroch
    Medicinal Chemistry, Corporate Research, Research Center Europe, Schering AG, D 13342 Berlin, Germany
    Bioorg Med Chem Lett 14:743-6. 2004
    ..Fluorinated dihydroquinolines showed reduced basicity of the amidine function. Their syntheses and potencies as neuronal nitric oxide synthase (n-NOS) inhibitors are reported...
  8. ncbi request reprint Dihydroquinolines as novel n-NOS inhibitors
    Stefan Jaroch
    Department of Medicinal Chemistry, Corporate Research, Schering AG, D 13342 Berlin, Germany
    Bioorg Med Chem Lett 12:2561-4. 2002
    ..Dihydroquinolines have been synthesized and have been shown to be potent n-NOS inhibitors. Selectivity versus e-NOS was increased to approximately 100-fold through appropriate substitution at the benzene ring...
  9. ncbi request reprint Dihydroquinolines with amine-containing side chains as potent n-NOS inhibitors
    Stefan Jaroch
    Department of Medicinal Chemistry, Research Center Europe, Corporate Research, Schering AG, D 13342, Berlin, Germany
    Bioorg Med Chem Lett 13:1981-4. 2003
    ..Dihydroquinolines with aminoalkyl side chains have been synthesized and have been shown to be potent n-NOS inhibitors. A marked selectivity versus e-NOS of up to approximately 300-fold was observed, whereas i-NOS was moderately inhibited...